Key result
In Egyptian nonmetastatic cancer patients, Factor V and MTHFR mutations were associated with an increased risk of venous thromboembolism and worsened overall survival.
Why the study?
Do thrombophilic gene mutations increase the risk of VTE and mortality in Egyptian nonmetastatic cancer patients?
Case-Control (n=80)
Do thrombophilic gene mutations increase the risk of VTE and mortality in Egyptian nonmetastatic cancer patients?
Factor V Leiden and MTHFR mutations are associated with an increased risk of VTE and higher mortality in Egyptian nonmetastatic cancer patients.
Answers are grounded in this paper and cite their sources.
FVL/MTHFR mutations were associated with VTE risk and mortality in this small Egyptian cohort; leaves open whether testing should guide prophylaxis.
Venous thromboembolism (VTE) is a common complication in cancer patients. Several genetic risk factors related to thrombophilia are known; however, their contributions to thrombotic tendency in cancer patients have conflicting results. We aimed to determine the prevalence of factor V Leiden (FVL), prothrombin (PTH) G20210A and methylene tetrahydrofolate reductase (MTHFR) C677T gene polymorphisms in Egyptian nonmetastatic cancer patients and their influence on thrombosis risk in those patients. Factor V Leiden, PTH G20210A and MTHFR C677T polymorphisms were detected in 40 cancer patients with VTE (group 1) and 40 cancer patients with no evidence of VTE (group 2) by PCR-based DNA analysis. Factor V and MTHFR mutations were higher in group 1 than in group 2 (factor V heterozygous mutation: 20 vs. 7.5%, homozygous mutation: 10 vs. 2.5%; MTHFR heterozygous mutation: 40 vs. 25%, homozygous mutation 5 vs. 0%, respectively) (P = 0.03). Mortality rate was higher in group 1 (75%) than in group 2 (25%; P < 0.001). No difference was found between those groups regarding PTH mutation (P = 1). Mortality rate was higher in the presence of homozygous and heterozygous factor V mutation (100 and 82%, respectively) compared to the wild type (41%) (P = 0.0006). Having any of the three studied gene mutations worsened the overall survival (P = 0.0003). Cox regression proved that both thrombosis and presence of factor V mutation are independent factors affecting survival in cancer patients (P < 0.001 and P = 0.01, respectively). In conclusion, there is an association between factor V and MTHFR mutations and risk of VTE in Egyptian cancer patients. Thrombosis and presence of factor V mutation are independent factors that influence survival in those patients.
No takes yet. Share an insight, caveat, or question.
Wahba et al. (2015) conducted a case-control in Nonmetastatic cancer (n=80). Thrombophilic gene mutations (Factor V Leiden, PTH G20210A, MTHFR C677T) vs. Absence of mutations (wild type) was evaluated on Presence of Factor V and MTHFR mutations (p=0.03). In Egyptian nonmetastatic cancer patients, Factor V and MTHFR mutations were associated with an increased risk of venous thromboembolism and worsened overall survival.
Synapse has enriched 10 related papers. Consider them for comparative context: